Lode Debrabandere

Lode Debrabandere

Lode Debrabandere

Founder & CEO - Amynas

Dr. Lode Debrabandere, Ph.D., M.B.A, is a serial entrepreneur. He serves as the Founder and CEO of Amynas, BV a Belgium based company focused on improving outcomes post surgical implant procedures and of 3RBiomed LLC,  a US based biotech company developing nanofiber implants for peripheral nerve repair based on IP from Johns Hopkins.

Between 2016 and 2018, Dr. Debrabandere served as the President & Chief Executive Officer of Aziyo Biologics, a fully integrated regenerative medicine company focused on the development and commercialization of products in orthopedic and cardiovascular specialties. Under his leadership, the company integrated the acquisition of a large tissue bank (Tissue Bank International) and acquired CorMatrix, Inc., adding a commercial sales team of 52 professionals and a portfolio of regenerative devices in cardiology and electrophysiology. Prior to Aziyo Biologics, between 2013 and 2016, he served as President & CEO of Osiris Therapeutics, a publicly traded regenerative medicine company developing and commercializing therapeutic products based on mesenchymal stem cells. The company focused on healing Diabetic Foot Ulcers and under his leadership grew revenue from $7 Million to over $100 Million (The company was acquired by Smith & Nephew for $660 Million). Prior, he also served as Osiris’ Chief Operating Officer.  Under his leadership  the company closed on multiple large transactions, incl. partnerships with Sanofi (previously Genzyme) for up to $1.1 Billion ($130 Million upfront), Nuvasive ($85 Million) and Mesoblast ($100 Million). 

Prior to Osiris, Dr. Debrabandere served between 2002 and 2006 as Vice President of Marketing at Bristol-Myers Squibb. He led the global Neuroscience Business Unit and was the Global Brand Leader for Abilify, the second largest brand of the company, behind Plavix. Prior to Bristol-Meyers Squibb, Dr. Debrabandere had leadership roles UCB Pharma, S.A. In 1995, he was expatriated by UCB Pharma S.A. from Brussels, Belgium to Atlanta, GA to establish UCB’s presence in the US.  He led the Marketing department of UCB Pharma Inc. in the US, focusing on allergy/respiratory (Zyrtec) and neurology (Keppra). While at UCB Pharma, Inc., he also held various roles of increasing levels of responsibility in the Research and Development department, including Director of Global Clinical Operations, overseeing all clinical development activities in the U.S., Europe, and Japan. Dr. Debrabandere earned an M.B.A., a Ph.D. in pharmaceutical sciences, toxicology, and a Pharm. D. degree, from the Catholic University of Leuven, Belgium. 

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners